Literature DB >> 9453566

CuZn-superoxide dismutase, extracellular superoxide dismutase, and glutathione peroxidase in blood from individuals homozygous for Asp90Ala CuZu-superoxide dismutase mutation.

P M Andersen1, P Nilsson, L Forsgren, S L Marklund.   

Abstract

The Asp90Ala CuZn-superoxide dismutase mutation is associated with amyotrophic lateral sclerosis (ALS) in both homo- and heterozygous form. We analyzed antioxidant enzymes in blood from 44 individuals homozygous and 114 individuals heterozygous for the Asp90Ala mutation as well as 66 blood relatives carrying the wild-type allele only. Erythrocyte CuZn-superoxide dismutase activity was reduced by 9% in the homozygous individuals, confirming previous findings on a smaller cohort. The specific activity of Asp90Ala mutant CuZn-superoxide dismutase in erythrocytes was equal to that of isolated mutant enzyme and slightly higher than that of isolated wild-type enzyme. There was no evidence for the presence of inactive mutant molecules in erythrocytes, and the lower activity is due to the occurrence of fewer active molecules. There were no significant differences between the groups in plasma extracellular superoxide dismutase content, and the erythrocyte glutathione peroxidase activities were virtually identical. Also, there were no differences in these parameters between homozygous individuals with or without ALS. There was no evidence for any association with ALS of a polymorphic extracellular superoxide dismutase mutation, Arg213Gly. The absence of response of the blood antioxidant enzymes to the Asp90Ala CuZn-superoxide dismutase mutation does not support the theory that the ALS-linked CuZn-superoxide dismutase mutations cause disease by increased oxidant stress.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9453566     DOI: 10.1046/j.1471-4159.1998.70020715.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  Epidemiologic evidence of oxidative stress in the brain.

Authors:  Lenore J Launer
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

2.  Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1(G93A) mice model.

Authors:  Marcelo R Vargas; Delinda A Johnson; Jeffrey A Johnson
Journal:  Neurobiol Dis       Date:  2011-05-06       Impact factor: 5.996

Review 3.  Mathematical and computational models of oxidative and nitrosative stress.

Authors:  Mahendra Kavdia
Journal:  Crit Rev Biomed Eng       Date:  2011

4.  SOD1 deficiency: a novel syndrome distinct from amyotrophic lateral sclerosis.

Authors:  Julien H Park; Christiane Elpers; Janine Reunert; Michael L McCormick; Julia Mohr; Saskia Biskup; Oliver Schwartz; Stephan Rust; Marianne Grüneberg; Anja Seelhöfer; Ulrike Schara; Eugen Boltshauser; Douglas R Spitz; Thorsten Marquardt
Journal:  Brain       Date:  2019-08-01       Impact factor: 13.501

Review 5.  Risk factors for amyotrophic lateral sclerosis.

Authors:  Caroline Ingre; Per M Roos; Fredrik Piehl; Freya Kamel; Fang Fang
Journal:  Clin Epidemiol       Date:  2015-02-12       Impact factor: 4.790

Review 6.  Neurotrophic and Neuroregenerative Effects of GH/IGF1.

Authors:  Vittorio Emanuele Bianchi; Vittorio Locatelli; Laura Rizzi
Journal:  Int J Mol Sci       Date:  2017-11-17       Impact factor: 5.923

7.  Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations.

Authors:  Dale J Lange; Mona Shahbazi; Vincenzo Silani; Albert C Ludolph; Jochen H Weishaupt; Senda Ajroud-Driss; Kara G Fields; Rahul Remanan; Stanley H Appel; Claudia Morelli; Alberto Doretti; Luca Maderna; Stefano Messina; Ulrike Weiland; Stefan L Marklund; Peter M Andersen
Journal:  Ann Neurol       Date:  2017-06-09       Impact factor: 10.422

Review 8.  Altered Mitochondrial Dynamics in Motor Neuron Disease: An Emerging Perspective.

Authors:  Manohar Kodavati; Haibo Wang; Muralidhar L Hegde
Journal:  Cells       Date:  2020-04-24       Impact factor: 6.600

Review 9.  Therapy development for spinal muscular atrophy: perspectives for muscular dystrophies and neurodegenerative disorders.

Authors:  Sibylle Jablonka; Luisa Hennlein; Michael Sendtner
Journal:  Neurol Res Pract       Date:  2022-01-04

10.  SOD-1 Variants in Amyotrophic Lateral Sclerosis: Systematic Re-Evaluation According to ACMG-AMP Guidelines.

Authors:  Paola Ruffo; Benedetta Perrone; Francesca Luisa Conforti
Journal:  Genes (Basel)       Date:  2022-03-18       Impact factor: 4.096

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.